Oncolytic adenovirus expressing a bispecific T cell adaptor, construction method and application
By constructing an oncolytic adenovirus expressing B7H3×CD3 BiTE, and utilizing the oncolytic virus to specifically replicate and express BiTE in tumor cells, the limitations of the existing oncolytic virus treatment efficacy and the application restrictions of BiTE in solid tumors were overcome, achieving effective killing and immune activation of tumors with high B7H3 expression.
Patent Information
- Application Number
- CN202311096077.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2022-08-31
- Filing Date
- 2023-08-29
- Publication Date
- 2026-11-10
- Estimated Expiration
- 2043-08-29
AI Technical Summary
Existing oncolytic virus therapies have limited efficacy, failing to effectively penetrate tumor tissue and activate immune responses. BiTE therapy in solid tumors is limited by physical barriers and immunosuppressive microenvironments, and there is a lack of oncolytic adenoviruses expressing B7H3×CD3 BiTE.
A novel oncolytic adenovirus was constructed, which controlled the expression cassettes of E1A and E1B genes via a human telomerase promoter and inserted the exogenous gene B7H3×CD3 BiTE. The oncolytic virus was used to specifically replicate and express BiTE in tumor cells, block the B7H3 molecule on the surface of tumor cells, and activate T cells to kill tumor cells.
It significantly enhanced the inhibitory ability against malignant tumors, improved the permeability and immune activation efficacy of BiTE in tumor tissues, and enhanced the therapeutic effect on tumors with high B7H3 expression.
Smart Images

Figure CN117025555B_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of biomedical technology, specifically relating to oncolytic adenovirus expressing a bispecific T cell connector, its construction method, and its uses. Background Technology
[0002] Oncolytic viruses (OVs) are a class of natural or genetically modified viruses that specifically kill tumor cells. They preferentially replicate within tumor cells, ultimately leading to tumor cell lysis and activating an anti-tumor immune response. The anti-tumor effects of these viruses in the body are generally believed to occur through two mechanisms: first, the specific replication of oncolytic viruses within tumor cells causes direct lysis of the tumor cells, releasing new viruses that infect and destroy other tumor cells; second, the release of large amounts of tumor antigens after lysing tumor cells, which, through antigen presentation, activate immune cells and generate an anti-tumor response. Oncolytic virus tumor therapy is a cutting-edge direction in tumor immunotherapy, demonstrating good safety and disruptive efficacy in clinical trials. Currently, representative oncolytic virus products have been approved for marketing, showing great potential and application prospects. Common oncolytic viruses include herpes simplex virus, adenovirus, vesicular stomatitis virus, poxvirus, and measles virus. The type of oncolytic virus currently undergoing the most clinical trials is oncolytic adenovirus. As of the first half of 2022, at least four oncolytic virus therapies had been approved for marketing globally: rigvir (ECHO-7 virus), Ancori (recombinant human adenovirus type 5), T-Vec (herpes simplex virus), and Delytact (herpes simplex virus). Oncolytic viruses exert their anti-tumor effects by specifically killing tumor cells and delivering tumor antigens. However, in addition to a large number of tumor cells, tumor tissue also contains a large number of stromal cells, including tumor vascular endothelial cells, fibroblasts, and suppressive immune cells. These cells constitute the tumor microenvironment and regulate the proliferation of tumor cells. Therefore, the efficacy of oncolytic virus monotherapy is limited.
[0003] B7-H3, also known as CD276, was initially shown to be induced in human dendritic cells (DCs) and to stimulate T cell proliferation, enhance the induction of cytotoxic T lymphocytes, and promote interferon-gamma secretion. However, subsequent studies have reported that human B7-H3 is a T cell co-inhibitory molecule, significantly inhibiting the secretion of IFN-γ, IL-2, IL-10, and IL-13 during T cell activation. B7-H3 knockout or blocking antibody antagonism can promote T cell proliferation and inhibit tumor growth. B7-H3 is highly expressed in various solid tumors and hematologic malignancies, including lung cancer, melanoma, pancreatic cancer, colorectal cancer, prostate cancer, ovarian cancer, renal cancer, glioma, and head and neck tumors. As a pan-tumor antigen and a potential immunosuppressive regulatory molecule, targeted therapy research against B7-H3 has become a hot topic in anti-tumor research in recent years.
[0004] Currently, B7-H3-targeted biologics entering clinical trials mainly include Fc-engineered antibodies, antibody-drug conjugates (ADCs), antibody-drug conjugates (ADCs), and CAR-T therapies. Among these, the most advanced is Y-mAbs Therapeutics' radionuclide-labeled B7-H3 monoclonal antibody 8H9 (Omburtamab), used to treat neuroblastoma with central nervous system / leptomeningeal metastases in children. Due to its excellent clinical efficacy, a marketing application has been submitted to the European Medicines Agency (EMA), and the company is also communicating with the FDA to supplement its application. Meanwhile, B7-H3-targeted ADC drugs have also achieved encouraging efficacy. For example, DS-7300, a B7-H3 ADC drug developed by Daiichi Sankyo in Japan, is conjugated with the DNA topoisomerase I inhibitor Dxd. Phase I / II clinical data showed that it has good safety and achieved clear and encouraging efficacy in metastatic castration-resistant prostate cancer. MacroGenics also reported early clinical data of their B7-H3 ADC drug MGC018 at the 2021 ASCO and ESMO conferences. MGC018 is conjugated with the DNA synthesis inhibitor duocarmycin. The results showed that MGC018 has manageable safety and observed a reduction in metastatic lesions in metastatic melanoma. MacroGenics has also developed Enoblituzumab, an Fc-engineered antibody targeting B7-H3, which is currently undergoing a Phase II clinical trial to evaluate the therapeutic effects of monotherapy and combination therapy with PD-1 and other antibodies on various solid tumors.
[0005] In 1960, Nisonoff first proposed the concept of bispecific antibodies (BsAbs). With the rapid advancements in genetic engineering antibodies, immunology, and related fields, the construction concepts, technological platforms, and product development of BsAbs have continuously evolved and innovated. Bispecific antibodies are artificial antibodies containing two specific antigen-binding sites. They can bridge the gap between target cells and functional molecules (cells), stimulating a directed immune response. A type of genetically engineered antibody, they have become a hot topic in antibody engineering and have broad application prospects in tumor immunotherapy. Bispecific T cell engagers (BiTEs) are bispecific antibodies formed by the fusion of the scFv fragments of two types of antibodies. They can bind to CD3 molecules or other activating factors on the surface of T cells and tumor cell surface antigen molecules, respectively, thereby inducing T cells to kill tumor cells. This process is not MHC-restricted. Currently, this therapy has shown good efficacy in hematological malignancies. One CD3×CD19 BiTE, Blinatumomab, has been approved by the FDA for the treatment of B-cell malignancies. However, BiTE typically has a short half-life in serum and may exhibit severe off-target toxicity. Furthermore, the physical barriers present in solid tumors and the immunosuppressive microenvironment limit the application of BiTE.
[0006] Oncolytic viruses can serve as a platform for gene engineering to express exogenous therapeutic genes. Developing oncolytic viruses specifically expressing BiTE (OVs-BiTE) allows for the continuous expression and secretion of BiTE by leveraging the self-replication and cytotoxic capabilities of OVs. Through specific gene modification, OVs can specifically target tumor cells, enabling more BiTE to penetrate tumor tissue and reduce off-target toxicity. This treatment method enhances the anti-tumor therapeutic ability of OVs and effectively overcomes the limitations of oncolytic viruses and BiTE. Currently, there are no reports of oncolytic adenoviruses expressing B7H3×CD3 BiTE. Summary of the Invention
[0007] This invention aims to at least solve one of the technical problems existing in the prior art. The purpose of this invention is to provide an oncolytic adenovirus expressing a bispecific T-cell connective, including oncolytic adenovirus E1A and E1B gene expression cassettes and a B7H3×CD3BiTE exogenous gene expression cassette.
[0008] Furthermore, the oncolytic adenovirus E1A is controlled by the human telomerase promoter hTERTp.
[0009] Furthermore, E1A connects to and initiates E1B expression through the internal ribosome entry site IRES, forming an oncolytic adenovirus with the structure hTERTp-E1A-IRES-E1B.
[0010] Furthermore, the oncolytic adenovirus E1A and E1B gene expression cassette includes the following operatively linked elements: human telomerase promoter hTERTp, E1A gene, IRES sequence, E1B gene, and terminator.
[0011] Furthermore, the nucleotide sequence of the human telomerase promoter hTERTp is shown in SEQ ID NO:1.
[0012] The nucleotide sequence of the oncolytic adenovirus E1A gene is shown in SEQ ID NO:2.
[0013] The amino acid sequence of the oncolytic adenovirus E1A gene is shown in SEQ ID NO:3.
[0014] The IRES nucleotide sequence is shown in SEQ ID NO:4.
[0015] The nucleotide sequence of the oncolytic adenovirus E1B gene is shown in SEQ ID NO:5.
[0016] The amino acid sequences of E1B19K and E1B55K encoded by the oncolytic adenovirus E1B gene are shown in SEQ ID NO:6 and SEQ ID NO:7.
[0017] The terminator of the oncolytic adenovirus E1A and E1B gene expression cassette is SV40 PolyA, and its nucleotide sequence is shown in SEQ ID NO:8.
[0018] Furthermore, the B7H3×CD3 BiTE exogenous gene includes a fusion gene of B7H3 scFv and CD3 scFv.
[0019] The B7H3 scFv includes the B7H3 scFv light chain variable region encoding sequence and the B7H3 scFv heavy chain variable region encoding sequence.
[0020] The CD3 scFv includes a CD3 scFv heavy chain variable region encoding sequence and a CD3 scFv light chain variable region encoding sequence.
[0021] Furthermore, the B7H3×CD3 BiTE exogenous gene expression cassette includes the following operatively linked elements: the coding sequence for the variable region of the B7H3 scFv light chain, the coding sequence for the variable region of the B7H3 scFv heavy chain, the coding sequence for the variable region of the CD3 scFv heavy chain, and the coding sequence for the variable region of the CD3 scFv light chain.
[0022] Preferably, the B7H3×CD3 BiTE exogenous gene expression cassette includes the following operatively linked elements: a promoter, a signal peptide coding sequence, a B7H3 scFv light chain variable region coding sequence, a linker sequence 1, a B7H3 scFv heavy chain variable region coding sequence, a linker sequence 2, a CD3 scFv heavy chain variable region coding sequence, a linker sequence 3, a CD3 scFv light chain variable region coding sequence, and a terminator.
[0023] Furthermore, the B7H3×CD3 BiTE exogenous gene expression cassette also includes a Kozak sequence preceding it, and the promoter includes a eukaryotic promoter. Preferably, the eukaryotic promoter is CMV, mCMV, or CAG.
[0024] Furthermore, the signal peptide is an Igκ signal peptide, and its nucleotide sequence is shown in SEQ ID NO:9.
[0025] Furthermore, the signal peptide is an Igκ signal peptide, and its amino acid sequence is shown in SEQ ID NO:10;
[0026] Furthermore, the nucleotide sequence of the B7H3 scFv light chain variable region is shown in SEQ ID NO:11 or SEQ ID NO:12.
[0027] Furthermore, the amino acid sequence of the variable region of the B7H3 scFv light chain is shown in SEQ ID NO:13 or SEQ ID NO:14.
[0028] Furthermore, the nucleotide sequence of the B7H3 scFv heavy chain variable region is shown in SEQ ID NO:15 or SEQ ID NO:16;
[0029] Furthermore, the amino acid sequence of the B7H3 scFv heavy chain variable region is shown in SEQ ID NO:17 or SEQ ID NO:18.
[0030] Furthermore, the linker peptide between the light chain variable region and the heavy chain variable region of the B7H3 scFv is (G4S)3, whose nucleotide sequence is shown in SEQ ID NO:19.
[0031] Furthermore, the amino acid sequence of the linker peptide (G4S)3 is shown in SEQ ID NO:20.
[0032] Furthermore, the nucleotide sequence of the CD3 scFv is shown in SEQ ID NO:21.
[0033] Furthermore, the amino acid sequence of the CD3 scFv is shown in SEQ ID NO:22.
[0034] Furthermore, the nucleotide sequence of the linker peptide between B7H3 scFv and CD3 scFv is shown in SEQ ID NO:23.
[0035] Furthermore, the amino acid sequence of the linker peptide between B7H3 scFv and CD3 scFv is shown in SEQ ID NO:24.
[0036] The present invention also provides a recombinant oncolytic adenovirus vector, which is operatively inserted into or contains the above-mentioned B7H3×CD3BiTE exogenous gene expression cassette.
[0037] The present invention also provides a method for constructing the oncolytic adenovirus expressing the above-mentioned bispecific T cell connector, comprising the following steps: cloning the synthesized E1A-E1B gene expression cassette into a shuttle vector to construct a plasmid containing E1A-E1B gene expression; cloning the synthesized B7H3×CD3 BiTE gene into the plasmid containing E1A-E1B gene expression; and then packaging the recombinant adenovirus to obtain a recombinant oncolytic adenovirus expressing B7H3×CD3 BiTE.
[0038] Preferably, the present invention also provides a method for constructing the oncolytic adenovirus expressing the above-mentioned bispecific T cell connector, comprising the following steps: synthesizing an E1A-E1B gene expression cassette, cloning the E1A-E1B gene expression cassette into a shuttle vector using the Gibson cloning method to construct a plasmid containing E1A-E1B gene expression, cloning the B7H3×CD3 BiTE gene into a pDC316 or pDC516 shuttle plasmid, and co-transfecting HEK293 cells with the pDC316 or pDC516 shuttle plasmid carrying the B7H3×CD3 BiTE gene and the backbone plasmid of the AdMax adenovirus packaging system to package recombinant adenovirus, thereby obtaining a recombinant oncolytic adenovirus expressing B7H3×CD3 BiTE.
[0039] More preferably, the backbone plasmid includes pBHGlox_E1,3Cre or pBHGfrt_E1,3Flp.
[0040] The present invention also provides the use of the oncolytic adenovirus or recombinant oncolytic adenovirus vector expressing the above-described bispecific T cell connective in the preparation of medicaments for the treatment and / or prevention and / or adjuvant treatment of cancer or tumors.
[0041] In the stated use, the drug is a preparation made by adding pharmaceutically acceptable excipients or auxiliary ingredients, with oncolytic adenovirus or recombinant oncolytic adenovirus vector as the anticancer active ingredient.
[0042] The formulations mentioned include, but are not limited to, injectable formulations and lyophilized formulations.
[0043] Preferably, the formulation is an injectable formulation.
[0044] The cancer or tumor is a tumor that highly expresses B7H3, including at least one of solid tumors, childhood-common tumors, or hematologic malignancies.
[0045] The solid tumors include at least one of melanoma, pancreatic cancer, colorectal cancer, prostate cancer, ovarian cancer, kidney cancer, glioma, or head and neck tumors.
[0046] The tumors commonly found in children include at least one of neuroblastoma, medulloblastoma, or osteosarcoma.
[0047] Beneficial Effects: Based on the genome of adenovirus type 5, this invention has modified an oncolytic adenovirus expressing a bispecific T-cell connective, including oncolytic adenovirus E1A and E1B gene expression cassettes and a B7H3×CD3BiTE exogenous gene expression cassette. Oncolytic adenovirus E1A is controlled by the human telomerase promoter (hTERTp), and E1A is linked to and initiates E1B expression via the internal ribosome entry site (IRES). Furthermore, the oncolytic virus incorporates an expression framework containing the bispecific T-cell connective BiTE targeting B7H3, enabling continuous expression of the B7H3×CD3 BiTE bifunctional antibody. This blockades the B7H3 molecule on the surface of tumor cells and stimulates T lymphocyte activation, thereby targeting and killing B7H3-positive tumor cells. In vitro and animal experiments demonstrate that, compared to gene therapy or oncolytic virus therapy alone, this invention, by combining a bispecific T-cell connective with an oncolytic virus, significantly enhances the inhibitory effect on malignant tumors. Attached Figure Description
[0048] Figure 1 The results of the in vitro oncolytic activity of oAd-B7H3-BiTE are shown in the figure. (A) After 72 hours of infection of HCT116 tumor cells with oAd-B7H3-BiTE at MOIs of 0, 1, 5, 10, and 20, the survival rate of tumor cells was quantitatively detected by CCK8 assay. (B) After 72 hours of infection of SW480 tumor cells with oAd-B7H3-BiTE at MOIs of 0, 1, 5, 10, and 20, the survival rate of tumor cells was quantitatively detected by CCK8 assay.
[0049] Figure 2The figure shows the blocking ability of B7H3-CD3 BiTE expressed by oAd-B7H3-BiTE on the surface of tumor cells after infection with tumor cells. Among them, (A) DLD-1, (B) RKO, (C) HCT116, (D) SW620 and (E) SW480 tumor cells were infected with oAd-B7H3-BiTE at MOI=10. After 48 hours, the expression of B7H3 on the surface of tumor cells was detected by flow cytometry to evaluate the blocking ability of B7H3-CD3 BiTE expressed by oAd-B7H3-BiTE on the surface of tumor cells after infection with tumor cells.
[0050] Figure 3 The diagram shows the activation effect of B7H3-CD3 BiTE expressed after oAd-B7H3-BiTE infection of tumor cells on human T lymphocytes; (A) CD4 + CD25 + T cell percentage, (B)CD4 + CD69 + T cell percentage, (C)CD8 + CD25 + T cell percentage, (D)CD8 + CD69 + T cell ratio;
[0051] Figure 4 The results of the targeted killing effect of B7H3-CD3 BiTE expressed by oAd-B7H3-BiTE on tumor cells are shown in the figure; (A) LDH-cytotoxicity assay to detect the cytotoxic killing effect of T cells on HCT116, (B) LDH-cytotoxicity assay to detect the cytotoxic killing effect of T cells on SW480, (C) LDH-cytotoxicity assay to detect the cytotoxic killing effect of T cells on DLD-1.
[0052] Figure 5 The results of the effect of B7H3-CD3 BiTE expressed after oAd-B7H3-BiTE infection of tumor cells on the proliferation of human T lymphocytes are shown in the figure; (A) fluorescence intensity of CFSE on CD3+ T cells, (B) number of CD3+ T cells.
[0053] Figure 6 Figure 1 shows the effect of B7H3-CD3 BiTE expressed by oAd-B7H3-BiTE on the ability of human T lymphocytes to secrete cytokines; (A) IFN-γ secretion and B.IL-2 secretion.
[0054] Figure 7The following are the effects of oAd-B7H3-BiTE treatment on tumor-bearing mice: (A) Dosing regimen, (B) Tumor volume growth curve, (C) Photograph of tumor in tumor-bearing mice, (D) Tumor weight statistics.
[0055] Figure 8 The infiltration of T cells within the tumor tissue; (A) CD4 in the tumor tissue after T cell injection alone. + CD8 + The proportion of T cells; (B) CD4 in tumor tissue after intratumoral administration of oAd-ON and tail vein injection of T cells. + CD8 + (C) The proportion of CD4+ and CD8+ T cells in tumor tissue after intratumoral administration of oAd-FHA-BiTE followed by tail vein injection of T cells; (D) The proportion of CD4+ and CD8+ T cells in tumor tissue after intratumoral administration of oAd-B7H3-BiTE followed by tail vein injection of T cells. + CD8 + The proportion of T cells; (E) Histogram representing oAd-B7H3-BiTE-induced CD4+ + T cell infiltration; (F) Histogram shows oAd-B7H3-BiTE-induced CD8 + T cell infiltration status;
[0056] Figure 9 The infiltration of Tregs in tumor tissue; (A) Multicolor flow cytometry reflects the proportion of Tregs cells in tumor tissue, (B) Histogram represents the proportion of Tregs cells in tumor tissue. Detailed Implementation
[0057] The inventors have dedicated themselves to the development and optimization of oncolytic adenoviruses. Through in-depth research and creative work, they have obtained an oncolytic adenovirus containing a recombinant exogenous therapeutic gene. Specifically, the E1A gene of this adenovirus is controlled by a human telomerase reverse transcriptase promoter; there is an IRES linker between the E1A and E1B genes, and the IRES promotes the expression of the E1B gene. An exogenous gene expression cassette is inserted after the adenovirus E1A and E1B gene expression cassettes. The exogenous gene is a fusion gene of B7H3 scFv and CD3 scFv, and the fusion gene is controlled by a constitutive strong promoter (such as CMV, mCMV, CAG promoter, etc.).
[0058] The inventors discovered that this oncolytic adenovirus, through effective control of its proliferation-essential genes—adenovirus E1A and E1B—by tumor-specific promoters, such as the human telomerase reverse transcriptase promoter, possesses the ability to selectively proliferate and replicate within tumor cells, specifically lysing tumor cells. Furthermore, this oncolytic adenovirus can efficiently express the exogenous gene B7H3×CD3 BiTE within tumor cells, which can bind to CD3 molecules on the surface of T cells and activate T cells. Simultaneously, it can bind to B7H3 antigen molecules on the surface of tumor cells, blocking the inhibition of T cells by B7H3 molecules on the tumor cell surface. This induces activated T cells to target and kill tumor cells, stimulates the body's anti-tumor immunity, enhances anti-tumor efficacy, and synergistically exerts anti-tumor effects. The recombinant oncolytic adenovirus provided by this invention can treat various types of malignant tumors.
[0059] In one embodiment of the present invention, the B7H3 scFv single-chain antibody is obtained through phage display technology. Hybridoma cells are obtained through animal immunization experiments, and cDNA is extracted from them. The heavy chain variable region (VH) and light chain variable region (VL) of the complete antibody matrix are obtained using reverse transcription PCR (RT-PCR). The VH and VL fragments are then spliced and amplified using overlap PCR (SOE-PCR) to obtain the single-chain antibody variable region gene fragment (scFv). The scFv gene is cloned into a suitable phage vector, electroporated into competent E. coli, and superstained with helper phages. The resulting supernatant is the single-chain antibody library. Using the specific antigen as a solid phase, after 3-5 rounds of "adsorption-elution-amplification" screening, enriched single-chain antibodies that specifically bind to the antigen are obtained. In some embodiments, the nucleotide sequence of the light chain variable region (VL) of B7H3scFv is shown in SEQ ID NO: 11 and SEQ ID NO: 12, and the amino acid sequences are shown in SEQ ID NO: 13 and SEQ ID NO: 14, respectively; the nucleotide sequence of the heavy chain variable region (VH) of B7H3scFv is shown in SEQ ID NO: 15 and SEQ ID NO: 16, and the amino acid sequences are shown in SEQ ID NO: 17 and SEQ ID NO: 18. The B7H3scFv antibody includes a heavy chain variable domain sequence, a light chain variable domain sequence, or a CDR sequence, and may have at least 70%, at least 80%, at least 90%, or at least 95% homology with the amino acid or nucleic acid sequences disclosed herein.
[0060] In one embodiment of the present invention, an oncolytic adenovirus expressing B7H3×CD3 BiTE (oAd-B7H3-BiTE) is provided. The E1A of this oncolytic adenovirus is controlled by a human telomerase promoter (hTERTp), and E1A is linked through an internal ribosome entry site (IRES) to initiate E1B expression, forming an oncolytic adenovirus with the structure hTERTp-E1A-IRES-E1B. The exogenous gene expression cassette of B7H3×CD3 BiTE is inserted after the hTERTp-E1A-IRES-E1B expression cassette.
[0061] The oncolytic adenovirus carrying the B7H3×CD3 BiTE gene of this invention can specifically and rapidly replicate and proliferate within tumor cells, lysing tumor cells; at the same time, this oncolytic adenovirus can continuously express the B7H3×CD3 BiTE bifunctional antibody, which can block the B7H3 molecule on the surface of tumor cells and stimulate T lymphocyte activation; the oncolytic adenovirus expressing B7H3×CD3 BiTE can target and kill B7H3-positive tumor cells.
[0062] This invention relates to a recombinant oncolytic adenovirus vector, the structure of which has the following characteristics:
[0063] The oncolytic adenovirus E1A and E1B gene expression cassette includes the following operatively linked elements: human telomerase promoter (hTERTp), E1A gene, IRES sequence, E1B gene, and terminator.
[0064] The nucleotide sequence of the human telomerase promoter (hTERTp) is shown in SEQ ID NO:1;
[0065] The nucleotide sequence of the oncolytic adenovirus E1A gene is shown in SEQ ID NO:2;
[0066] The amino acid sequence of the oncolytic adenovirus E1A gene is shown in SEQ ID NO:3;
[0067] The IRES nucleotide sequence is shown in SEQ ID NO:4;
[0068] The nucleotide sequence of the oncolytic adenovirus E1B gene is shown in SEQ ID NO:5;
[0069] The amino acid sequences of E1B19K and E1B55K encoded by the oncolytic adenovirus E1B gene are shown in SEQ ID NO:6 and SEQ ID NO:7.
[0070] The nucleotide sequence of the oncolytic adenovirus E1A and E1B gene expression cassette SV40 PolyA is shown in SEQ ID NO:8.
[0071] In another aspect, the present invention relates to a recombinant oncolytic adenovirus vector, which is operatively inserted with or contains the following exogenous gene:
[0072] The B7H3×CD3 BiTE exogenous gene expression cassette includes the following operatively linked elements: promoter, signal peptide coding sequence, B7H3 scFv light chain variable region coding sequence, linker sequence 1, B7H3 scFv heavy chain variable region coding sequence, linker sequence 2, CD3 scFv heavy chain variable region coding sequence, linker sequence 3, CD3 scFv light chain variable region coding sequence, and terminator.
[0073] The B7H3×CD3 BiTE exogenous gene expression cassette also includes a Kozak sequence, and the promoters include, but are not limited to, eukaryotic promoters such as CMV, mCMV, and CAG.
[0074] The signal peptide is an Igκ signal peptide, and its nucleotide sequence is shown in SEQ ID NO:9;
[0075] The signal peptide is an Igκ signal peptide, and its amino acid sequence is shown in SEQ ID NO:10.
[0076] The nucleotide sequence of the variable region of the B7H3 scFv light chain is shown in SEQ ID NO:11 and SEQ ID NO:12;
[0077] The amino acid sequence of the B7H3 scFv light chain variable region is shown in SEQ ID NO:13 and SEQ ID NO:14;
[0078] The nucleotide sequence of the B7H3 scFv heavy chain variable region is shown in SEQ ID NO:15 and SEQ ID NO:16;
[0079] The amino acid sequence of the B7H3 scFv heavy chain variable region is shown in SEQ ID NO:17 and SEQ ID NO:18;
[0080] The linker peptide between the light chain variable region and the heavy chain variable region of the B7H3 scFv is (G4S)3, and its nucleotide sequence is shown in SEQ ID NO:19.
[0081] The linker peptide between the light chain variable region and the heavy chain variable region of the B7H3 scFv is (G4S)3, and its amino acid sequence is shown in SEQ ID NO:20.
[0082] The nucleotide sequence of the CD3 scFv is shown in SEQ ID NO:21;
[0083] The amino acid sequence of the CD3 scFv is shown in SEQ ID NO:22;
[0084] The nucleotide sequence of the linker peptide between B7H3 scFv and CD3 scFv is shown in SEQ ID NO:23;
[0085] The amino acid sequence of the linker peptide between B7H3 scFv and CD3 scFv is shown in SEQ ID NO:24;
[0086] The present invention also provides a method for constructing the oncolytic adenovirus expressing the above-mentioned bispecific T cell connector, comprising the following steps: synthesizing an E1A-E1B gene expression cassette, cloning the E1A-E1B gene expression cassette into a shuttle vector using the Gibson cloning method, constructing a plasmid containing E1A-E1B gene expression, cloning the B7H3×CD3 BiTE gene into a pDC316 or pDC516 shuttle plasmid, and co-transfecting HEK293 cells with the pDC316 or pDC516 shuttle plasmid carrying the B7H3×CD3 BiTE gene and the backbone plasmids pBHGlox_E1,3Cre or pBHGfrt_E1,3Flp of the AdMax adenovirus packaging system to package recombinant adenovirus, thereby obtaining a recombinant oncolytic adenovirus expressing B7H3×CD3 BiTE.
[0087] Another aspect of the present invention relates to the use of the recombinant oncolytic adenovirus vector or recombinant oncolytic adenovirus of the present invention in the preparation of medicaments for the treatment and / or prevention and / or adjuvant treatment of cancer or tumors.
[0088] The cancers or tumors mentioned are tumors that highly express B7H3, including various solid tumors such as lung cancer, melanoma, pancreatic cancer, colorectal cancer, prostate cancer, ovarian cancer, kidney cancer, glioma, and head and neck tumors, as well as various tumors that are common in children such as neuroblastoma, medulloblastoma, and osteosarcoma, and even hematologic malignancies.
[0089] The following are nucleotide or amino acid sequences related to this invention.
[0090] SEQ ID NO:1 Human telomerase promoter (hTERTp) nucleotide sequence
[0091] TGGCCCCTCCCTCGGGTTACCCCACAGCCTAGGCCGATTCGACCTCTCTCCGCTGGGGCCCTCGCTGGCGTCCCTGCACCCTGGGAGCGCGAGCGGCGCGCGGGCGGGGAAGCGCGGCCCAGACCCCCGGGTCCGCCCGGAGCAGCTGCGCTGTCGGGGCCAGGCCGGGCTCCCAGTGGATTCGCGGGCACAGACGCCCAGGACCGCGCTTCCCACGTGGCGGAGGGACTGGGGACCCGGGCACCCGTCCTGCCCCTTCACCTTCCAGCTCCGCCTCCTCCGCGCGGACCCCGCCCCGTCCCGACCCCTCCCGGGTCCCCGGCCCAGCCCCCTCCGGGCCCTCCCAGCCCCTCCCCTTCCTTTCCGCGGCCCCGCCCTCTCCTCGCGGCGCGAGTTTCAGGCAGCGCTGCGTCCTGCTGCGCACGTGGGAAGCCCTGGCCCCGGCCACCCCCGCG
[0092] SEQ ID NO:2 Nucleotide sequence of the oncolytic adenovirus E1A gene
[0093] ATGAGACATATTATCTGCCACGGAGGTGTTATTACCGAAGAAATGGCCGCCAGTCTTTTGGACCAGCTGATCGAAGAGGTACTGGCTGATAATCTTCCACCTCCTAGCCATTTTGAACCACCTACCCTTCACGAACTGTATGATTTAGACGTGACGGCCCCCGAAGATCCCAACGAGGAGGCGGTTTCGCAGATTTTTCCCGACTCTGTAATGTTGGCGGTGCAGGAAGGGATTGACTTACTCACTTTTCCGCCGGCGCCCGGTTCTCCGGAGCCGCCTCACCTTTCCCGGCAGCCCGAGCAGCCGGAGCAGAGAGCCTTGGGTCCGGTTTCTATGCCAAACCTTGTACCGGAGGTGATCGATCTTACCTGCCACGAGGCTGGCTTTCCACCCAGTGACGACGAGGATGAAGAGGGTGAGGAGTTTGTGTTAGATTATGTGGAGCACCCCGGGCACGGTTGCAGGTCTTGTCATTATCACCGGAGGAATACGGGGGACCCAGATATTATGTGTTCGCTTTGCTATATGAGGACCTGTGGCATGTTTGTCTACAGTAAGTGAAAATTATGGGCAGTGGGTGATAGAGTGGTGGGTTTGGTGTGGTAATTTTTTTTTTAATTTTTACAGTTTTGTGGTTTAAAGAATTTTGTATTGTGATTTTTTTAAAAGGTCCTGTGTCTGAACCTGAGCCTGAGCCCGAGCCAGAACCGGAGCCTGCAAGACCTACCCGCCGTCCTAAAATGGCGCCTGCTATCCTGAGACGCCCGACATCACCTGTGTCTAGAGAATGCAATAGTAGTACGGATAGCTGTGACTCCGGTCCTTCTAACACACCTCCTGAGATACACCCGGTGGTCCCGCTGTGCCCCATTAAACCAGTTGCCGTGAGAGTTGGTGGGCGTCGCCAGGCTGTGGAATGTATCGAGGACTTGCTTAACGAGCCTGGGCAACCTTTGGACTTGAGCTGTAAACGCCCCAGGCCATAA
[0094] Amino acid sequence of the oncolytic adenovirus E1A gene (SEQ ID NO:3)
[0095] MRHIICHGGVITEEMAASLLDQLIEEVLADNLPPPSHFEPPTLHELYDLDVTAPEDPNEEAVSQIFPDSVMLAVQEGIDLLTFPPAPGSPEPPHLSRQPEQPEQRALGPVSMPNLVPEVIDLTCHEAGFPPSDDEDEEGEEFVL DYVEHPGHGCRSCHYHRRNTGDPDIMCSLCYMRTCGMFVYSPVSEPEPEPEPEPARPTRRPKMAPAILRRPTSPVSRECNSSTDSCDSGPSNTPPEIHPVVPLCPIKPVAVRVGGRRQAVECIEDLLNEPGQPLDLSCKRPRP
[0096] The E1A gene is transcribed into RNA, and then intron sequences are removed before it is translated into protein.
[0097] SEQ ID NO:4IRES nucleotide sequence
[0098] GCCCCTCTCCCTCCCCCCCCCCTAACGTTACTGGCCGAAGCCGCTTGGAATAAGGCCGGTGTGCGTTTGTCTATATGTTATTTTCCACCATATTGCCGTCTTTTGGCAATGTGAGGGCCCGGAAACCTGGCCCTGTCTTCTTGACGAGCATTCCTAGGGGTCTTTCCCCTCTCGCCAAAGGAATGCAAGGTCTGTTGAATGTCGTGAAGGAAGCAGTTCCTCTGGAAGCTTCTTGAAGACAAACAACGTCTGTAGCGACCCTTTGCAGGCAGCGGAACCCCCCACCTGGCGACAGGTGCCTCTGCGGCCAAAAGCCACGTGTATAAGATACACCTGCAAAGGCGGCACAACCCCAGTGCCACGTTGTGAGTTGGATAGTTGTGGAAAGAGTCAAATGGCTCTCCTCAAGCGTATTCAACAAGGGGCTGAAGGATGCCCAGAAGGTACCCCATTGTATGGGATCTGATCTGGGGCCTCGGTGCACATGCTTTACATGTGTTTAGTCGAGGTTAAAAAAACGTCTAGGCCCCCCGAACCACGGGGACGTGGTTTTCCTTTGAAAAACACGATGATAATATGGCCACAACC
[0099] Nucleotide sequence of the oncolytic adenovirus E1B gene set forth in SEQ ID NO:5
[0100]
[0101] SEQ ID NO:6 Amino acid sequence of E1B19K encoded by the oncolytic adenovirus E1B gene
[0102] MEAWECLEDFSAVRNLLEQSSNSTSWFWRFLWGSSQAKLVCRIKEDYKWEFEELLKSCGELFDSLNLGHQALFQEKVIKTLDFSTPGRAAAAVAFLSFIKDKWSEETHLSGGYLLDFLAMHLWRAVVRHKNRLLLLSSVRPAIIPTEEQQQQQEEARRRRQEQSPWNPRAGLDPRE
[0103] SEQ ID NO:7 Amino acid sequence of E1B55K encoded by the oncolytic adenovirus E1B gene
[0104] MERRNPSERGVPAGFSGHASVESGCETQESPATVVFRPPGDNTDGGAAAAAGGSQAAAAGAEPMEPESRPGPSGMNVVQVAELYPELRRILTITEDGQGLKGVKRERGACEATEEARNLAFSLM TRHRPECITFQQIKDNCANELDLLAQKYSIEQLTTYWLQPGDDFEEAIRVYAKVALRPDCKYKISKLVNIRNCCYISGNGAEVEIDTEDRVAFRCSMINMWPGVLGMDGVVIMNVRFTGPNFSG TVFLANTNLILHGVSFYGFNNTCVEAWTDVRVRGCAFYCCWKGVVCRPKSRASIKKCLFERCTLGILSEGNSRVRHNVASDCGCFMLVKSVAVIKHNMVCGNCEDRASQMLTCSDGNCHLLKTI HVASHSRKAWPVFEHNILTRCSLHLGNRRGVFLPYQCNLSHTKILLEPESMSKVNLNGVFDMTMKIWKVLRYDETRTRCRPCECGGKHIRNQPVMLDVTEELRPDHLVLACTRAEFGSSDEDTD
[0105] The E1B gene is transcribed into RNA, and then intron sequences are removed before it is translated into protein.
[0106] SEQ ID NO:8SV40 PolyA nucleotide sequence
[0107] CAGACATGATAAGATACATTGATGAGTTTGGACAAACCACAACTAGAATGCAGTGAAAAAAATGCTTTATTTGTGAAATTTGGTGATGCTATTGCTTTATTTGTAACCATTATAAGCTGCAATAAACAAGTTAACAACAACAATTGCATTCATTTTATGTTTCAGGTTCAGGGGGAGGTGTGGGAGGTTTTTTAAAGCAAGTAAAACCTCTACAAATGTGGTA
[0108] Nucleotide sequence of SEQ ID NO:9 Igκ signal peptide
[0109] ATGGAGACAGACACACTCCTGCTATGGGTGCTGCTGCTCTGGGTTCCAGGTTCCACTGGTGAC
[0110] Amino acid sequence of SEQ ID NO:10 Igκ signal peptide
[0111] METDTLLLWVLLLWVPGSTGD
[0112] SEQ ID NO:11B7H3 scFv light chain variable region nucleotide sequence (1)
[0113] GACATTTGTGATGTCACAGTCTCCATCCTCCCTAGCTGTGTCAGTTGGAGAGAAGGTTACTATGAGCTGCAAGTCCAGTCAGAGCCTTTTATATAGTAGCAATCAAAAGAACTACTTGGCCTGGTACCAGCAGAAACCAGGGCAGTCTCCTAAACTGCTGATTTACTGGG CATCCACTAGGGAATCTGGGGTCCCTGATCGCTTCACAGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTGTGAAGGCTGAAGACCTGGCAGTTTTATTACTGTCAGCAATATTATAGCTATCCATTCACGTTCGGCTCGGGTACCAAGGTGGAGATCAAG
[0114] SEQ ID NO:12B7H3 scFv light chain variable region nucleotide sequence (2)
[0115] CAAATTGTTCTCACCCAGTCTCCAGCAATCATGTCTGCCTCCAGGGGAGAAGGTCACCATGACCTGCAGTGCCAGTTCAAGTGTAAGTCTCATGCACTGGTACCAGCAGAAGTCGGACACCTCCCCCAAAAGATGGATTTATGACACATCCAAACTG GCTTCTGGAGTCCCTGCTCGCTTCAGTGGCAGTCGGTCTGGGACCTCTTATTCTCTCACAATCAGCAGCATGGAGGCTGAAGATGCTGCCACTTATTACTGTCAGCAGTGGAGTGATAACCCGCTCACGTTCGGTGCTGGTACCAAGGTGGAGATCAAG
[0116] SEQ ID NO:13B7H3 scFv light chain variable region amino acid sequence (1)
[0117] DIVMSQSPSSLAVSVGEKVTMSCKSSQSLLYSSNQKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVKAEDLAVYYCQQYYSYPFTFGSGTKVEIK
[0118] SEQ ID NO:14B7H3 scFv light chain variable region amino acid sequence (2)
[0119] QIVLTQSPAIMSASPGEKVTMTCSASSSVSLMHWYQQKSDTSPKRWIYDTSKLASGVPARFSGSRSGTSYSLTISSMEAEDAATYYCQQWSDNPLTFGAGTKVEIK
[0120] SEQ ID NO:15B7H3 scFv heavy chain variable region nucleotide sequence (1)
[0121] GAGGTGCAGCTGCAGGAGTCTGGAGCTGAGCTGGTGAAGCCTGGGGCTTCAGTGAAGCTGTCCTGCAAGACTTCTGGCTACACCTTCACCAACTACTGGATTCAGTGGATAAAACAGAGGCCTGGACAGGGCCTTGGATGGATTGGAGAGATATTTCCTGTAACTGGCACTACTTACTACAATGAGAAGTTCAAGGGCAAGGCCACACTGACTATAGACACATCCTCCAGCACAGCCTACATGCAGCTCAGCAGCCTGACCTCTGAGGACTCTGCTGTCTATTTCTGTGCAAGAACGGGGACAGCTCGGGCTCAGTTTGCTTACTGGGGCCAAGGGACTCTGGTCACTGTCTCGAGT
[0122] SEQ ID NO: 16 B7H3 scFv heavy chain variable region nucleotide sequence (2)
[0123] GAGGTGCAGCTGCAGGAGTCTGGACCTGAGAAGGTGAAGCCTGGGGCTTCAGTGAAGATATCCTGCAAGACTTCTGGATACACATTCACTGAATACACCATGCACTGGGTGAAGCAGAGCCATGGAAAGAGCCTTGAGTGGATTGGAGGTATTAATCCTAACAGTGGTGGTACTACCTACAACCAGAAGTTCAAGGGCAAGGCCACATTGACTGTAGACAAGTCCTCCAGCACAGCCTACATGGAACTCCGCAGCCTGACATCTGAGGATTCTGCAGTCTATTACTGTACAAGAGTGGGGGGACCATGGCCCACGACGAGGGGTATGGACTACTGGGGTGAAGGAACCTCAGTCACCGTCTCGAGT
[0124] SEQ ID NO: 17 B7H3 scFv heavy chain variable region amino acid sequence (1)
[0125] EVQLQESGAELVKPGASVKLSCKTSGYTFTNYWIQWIKQRPGQGLGWIGEIFPVTGTTYYNEKFKGKATLTIDTSSSTAYMQLSSLTSEDSAVYFCARTGTARAQFAYWGQGTLVTVSS
[0126] SEQ ID NO:18B7H3 scFv Heavy Chain Variable Region Amino Acid Sequence (2)
[0127] EVQLQESGPEKVKPGASVKISCKTSGYTFTEYTMHWVKQSHGKSLEWIGGINPNSGGTTYNQKFKGKATLTVDKSSSTAYMELRSLTSEDSAVYYCTRVGGPWPTTRGMDYWGEGTSVTVSS
[0128] SEQ ID NO:19B7H3 scFv linker peptide (G4S) 3 nucleotide sequence between the light chain variable region and the heavy chain variable region
[0129] GGCGGCGGCGGCTCCGGAGGAGGAGGAAGCGGAGGAGGCGGCAGC
[0130] SEQ ID NO:20B7H3 scFv Linker peptide (G4S) 3 amino acid sequence between the light chain variable region and the heavy chain variable region
[0131] GGGGSGGGGSGGGGS
[0132] Nucleotide sequence of SEQ ID NO:21CD3 scFv
[0133] GACATCAAGCTGCAGCAGTCAGGGCTGAACTGGCCAGGCCTGGGGCTTCAGTGAAGATGTCCTGCAAGACCTCTGGCTACACCTTCACCAGATACACCATGCACTGGGTGAAGCAGAGGCCTGGACAAGGCCTTGAGTGGATCGGATACATTAACCCTTCTAGAGGCTATACTAACTACAAT CAAAAGTTCAAGGACAAGGCCACATTGACTACCGACAAGTCCTCCAGCACAGCCTACATGCAGCTCAGCAGCCTGACATCTGAGGACTCTGCGGTCTATTACTGTGCCAGATATTACGACGACCACTATTGCCTGGACTACTGGGGCCAAGGCACCACGCTGACCGTCAGCAGCGTGGAGGGC The nucleotide sequence of CD3 scFv is the coding sequence for the CD3 scFv heavy chain variable region, linker sequence 1, and CD3 scFv light chain variable region. Among them, linker sequence 1 is the linker peptide (G2S)4.
[0134] The amino acid sequence of SEQ ID NO:22CD3 scFv
[0135] DIKLQQSGAELARPGASVKMSCKTSGYTFTRYTMHWVKQRPGQGLEWIGYINPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYCLDYWGQGTTLTVSSVE GGSGGSGGSGGSGGVDDIQLTQSPAIMSASPGEKVTMTCRASSSVSYMNWYQQKSGTSPKRWIYDTSKVASGVPYRFSGGSGTSYSLTISSMEAEDAATYYCQQWSSNPLTFGAGTKLELK
[0136] Nucleotide sequence of the linker peptide between SEQ ID NO:23B7H3 scFv and CD3 scFv
[0137] GAATTCAGCAGCGGCGGAGGCGGAAGC
[0138] Amino acid sequence of the linker peptide between SEQ ID NO:24B7H3 scFv and CD3 scFv
[0139] EFSSGGGGS
[0140] The present invention will be explained below with reference to embodiments. Those skilled in the art will understand that the following embodiments are for illustrative purposes only and should not be considered as limiting the scope of the invention. Where specific techniques or conditions are not specified in the embodiments, they are performed according to the techniques or conditions described in the literature in the field or according to the product instructions. Reagents or instruments whose manufacturers are not specified are all conventional products that can be obtained commercially.
[0141] Example 1: Construction of recombinant oncolytic adenovirus expressing B7H3×CD3 BiTE (oAd-B7H3-BiTE)
[0142] (1) Based on the human telomerase promoter hTERTp (SEQ ID NO:1), E1A gene (SEQ ID NO:2), IRES sequence (SEQ ID NO:4), E1B gene (SEQ ID NO:5), and SV40 PolyA terminator (SEQ ID NO:8), the E1A-E1B gene expression cassette was synthesized, i.e., the combination of SEQ ID NO:1+SEQ ID NO:2+SEQ ID NO:4+SEQ ID NO:5+SEQ ID NO:8. The E1A-E1B gene expression cassette was cloned into a shuttle vector such as pDC316 or pDC516 using the Gibson cloning method. The constructed plasmid was named pDC316-hTERTp-E1AE1B or pDC516-hTERTp-E1AE1B.
[0143] (2) Based on the sequence of the B7H3×CD3 BiTE gene (shown in SEQ ID NO:9, SEQ ID NO:12, SEQ ID NO:16, SEQ ID NO:19 and SEQ ID NO:21, SEQ ID NO:23), the sequence of the B7H3×CD3 BiTE gene was synthesized, namely the combination of SEQ ID NO:9+SEQ ID NO:12+SEQ ID NO:19+SEQ ID NO:16+SEQ ID NO:23+SEQ ID NO:21. The B7H3×CD3 BiTE gene was cloned into the pDC316-hTERTp-E1AE1B or pDC516-hTERTp-E1AE1B vector using molecular cloning. The successfully constructed plasmid was named pDC316-E1AE1B-B7H3-BiTE or pDC516-E1AE1B-B7H3-BiTE. Simultaneously, a fusion gene of pertussis filamentous hemagglutinin (FHA) scFv and CD3 scFv was synthesized and named FHA-BiTE as a control BiTE. The nucleotide sequence of FHA-BiTE is: SEQ ID NO:25:
[0144]
[0145] 1) First, the plasmids pUC-B7H3-BiTE or pUC-FHA-BiTE containing the B7H3×CD3 BiTE or FHA×CD3 BiTE gene were digested with Sal I restriction endonuclease. After agarose gel electrophoresis, the B7H3-BiTE or FHA-BiTE gene fragments were excised and recovered.
[0146] 2) The pDC316-hTERTp-E1AE1B or pDC516-hTERTp-E1AE1B plasmid was digested with Sal I restriction endonuclease, and the pDC316-hTERTp-E1AE1B or pDC516-hTERTp-E1AE1B vector fragment was recovered by gel excision after agarose gel electrophoresis.
[0147] 3) Take 50 ng of the digested pDC316-hTERTp-E1AE1B or pDC516-hTERTp-E1AE1B vector fragment and 3 times the molar amount of B7H3-BiTE or FHA-BiTE insert fragment, adjust the total volume to 10 μL with double-distilled water, add 10 μL of 2× ligation buffer and 1 μL of T4 DNA ligase, react at room temperature for 10 minutes, and then transform into DH5α competent cells.
[0148] 4) The next day, clones were picked and verified by colony PCR. Clones with positive PCR results were cultured and plasmids were extracted and digested with enzymes for verification. Plasmids with correct enzyme digestion were further verified by sequencing. Plasmids with correct sequencing results were named pDC316-E1AE1B-B7H3-BiTE or pDC516-E1AE1B-B7H3-BiTE, and the control BiTE shuttle plasmid was named pDC316-E1AE1B-FHA-BiTE or pDC516-E1AE1B-FHA-BiTE.
[0149] (3) Packaging of recombinant adenovirus
[0150] 1) The constructed shuttle plasmids pDC316-E1AE1B-B7H3-BiTE or pDC516-E1AE1B-B7H3-BiTE carrying the B7H3-BiTE gene, and the control BiTE shuttle plasmids pDC316-E1AE1B-FHA-BiTE or pDC516-E1AE1B-FHA-BiTE, were co-transfected with the AdMax adenovirus system backbone plasmids pBHGlox_E1,3Cre or pBHGfrt_E1,3Flp to HEK293 cells for recombinant adenovirus packaging. The process is as follows:
[0151] 1) 0.8-1×10 6HEK293 cells were seeded per well in six-well plates, cultured in high-glucose DMEM + 10% FBS medium, and incubated overnight at 37°C in a cell culture incubator containing 5% CO2.
[0152] 2) On the second day, change the medium with high-glucose DMEM + 2% FBS. Co-transfect HEK293 cells with 4 μg of the backbone plasmid (pBHGlox_E1,3Cre or pBHGfrt_E1,3Flp) and 2 μg of the shuttle plasmid using Lipofectamine 3000. Observe the cells for signs of cytotoxicity daily. Once the cells reach confluence, transfer them to a 25 cm⁻¹ medium. 2 After the cells have grown to a confluence in the cell culture flask, they are then transferred to a 75cm culture medium. 2 In cell culture flasks, cells are collected until obvious plaques appear and most of the cells become diseased and detach from the bottom.
[0153] 3) Collect the cell culture containing the virus, centrifuge at 1200 rpm for 3 minutes, and aspirate the virus-containing supernatant. Resuspend the cell pellet in 1 / 10 of the culture volume of virus-containing supernatant and freeze-thaw it three times in a -80°C freezer and a 37°C water bath. Centrifuge at 3000 rpm for 20 minutes, collect the virus-containing supernatant, and combine it with the aforementioned virus-containing supernatant. This is the seed virus for the adenovirus vaccine.
[0154] 4) Take 50 μL of vaccine candidate strain inoculum, add 2 μL of proteinase K, digest at 50℃ for 30 min to release the viral genome, use this as a template for PCR amplification of the target gene, and identify the PCR product by electrophoresis gel recovery and sequencing. The correctly identified target virus is named oAd-B7H3-BiTE, and the control BiTE virus is named oAd-FHA-BiTE; oAd-FHA-BiTE is the oncolytic adenovirus of the control BiTE. This virus expresses pertussis filamentous hemagglutinin (FHA) scFv and CD3 scFv, only CD3 scFv is active, and there is no B7H3 targeting.
[0155] Example 2: In vitro oncolytic activity of oAd-B7H3-BiTE
[0156] The oncolytic activity of oAd-B7H3-BiTE against tumor cells in vitro was detected using the CCK8 assay. The specific experimental steps are as follows: 1.5 × 10 4HCT116 or SW480 tumor cells were seeded into 96-well plates at 100 μL per well, with 3 replicates per group. After 24 hours of cell culture, tumor cells were infected with oAd-B7H3-BiTE, oAd-FHA-BiTE, and oAd at MOIs of 0, 1, 5, 10, and 20, respectively. 72 hours after viral infection, 10% CCK8 culture medium was prepared, the original culture medium was discarded, and 100 μL was added to each well. The cells were incubated at 37°C for 30 minutes, and the absorbance was measured at 450 nm. Cell viability was calculated using the following formula:
[0157] Cell viability (%) = [(As-Ab) / (Ac-Ab)] × 100, where As = absorbance of experimental wells (absorbance of wells containing cells, culture medium, CCK-8, and the test compound), Ab = absorbance of blank wells (absorbance of wells containing culture medium and CCK-8), and Ac = absorbance of control wells (absorbance of wells containing cells, culture medium, and CCK-8). Results showed that with increasing MOI, the survival rate of tumor cells infected with oAd-B7H3-BiTE, oAd-FHA-BiTE, and oAd viruses all decreased significantly. There was no significant difference in the oncolytic ability of oAd-B7H3-BiTE, oAd-FHA-BiTE, and the control virus oAd against HCT116 tumor cells. There was no significant difference in the oncolytic ability of oAd-FHA-BiTE and the control virus oAd against SW480 tumor cells, while oAd-B7H3-BiTE slightly reduced the oncolytic ability of SW480 tumor cells. Specific results are as follows: Figure 1 As shown.
[0158] Example 3: The ability of B7H3-CD3 BiTE expressed after oAd-B7H3-BiTE infection of tumor cells to block B7H3 on the surface of tumor cells.
[0159] HCT116, SW480, RKO, SW620, and DLD-1 cells were cultured at a rate of 1×10⁻⁶. 5Cells were seeded per well in 24-well plates and cultured overnight at 37°C in a 5% CO2 incubator. Five cell lines were infected with oAd-B7H3-BiTE at an MOI of 10, with one well left untreated as a negative control. Cells were cultured for another 48 hours at 37°C in a 5% CO2 incubator and then collected. After washing the cells twice with 1×PBS, the cell pellet was resuspended in 100 μL of 1×PBS, and APC-B7H3 flow cytometry antibody was added and incubated in the dark for 30 minutes. After washing the cells twice with 1×PBS, the expression of B7H3 in tumor cells was measured. Experimental results showed that after infection with various tumor cells using oAd-B7H3-BiTE, the expression rate of B7H3 protein on the surface of HCT116 tumor cells was 24.13%, SW620 tumor cells 31.18%, DLD-1 tumor cells 28.49%, SW480 tumor cells 41.77%, and RKO tumor cells 57.18%. This indicates that the B7H3-CD3BiTE expressed after oAd-B7H3-BiTE infection of B7H3-positive tumor cells can bind to B7H3 on tumor cells, thereby blocking the binding of APC-B7H3 flow cytometry antibody to B7H3 on the surface of tumor cells. This demonstrates that the B7H3-CD3BiTE expressed after oAd-B7H3-BiTE infection of tumor cells can block B7H3 on the surface of tumor cells. Specific results are as follows: Figure 2 As shown.
[0160] Example 4: Activation of T lymphocytes by B7H3-CD3 BiTE expressed after oAd-B7H3-BiTE infection of tumor cells.
[0161] Viruses oAd-B7H3-BiTE, oAd-FHA-BiTE, and oAd were used to infect 293A at an MOI of 10. The supernatant was collected after 48 hours and stored at -20°C for later use. 1.5 × 10⁻⁶ 4 HCT116 tumor cells were then placed in 96-well plates, followed by infection of the tumor cells with 100 μL of viral supernatant, and then 7.5 × 10⁶ HCT116 tumor cells were added. 4 T cells (E:T = 5:1) were collected, with the CD3 / CD28 antibody treatment group serving as the positive control. Cells were collected after day 4, and the expression of CD3, CD4, CD8, CD25, and CD69 was detected by flow cytometry to assess T cell activation. Results showed that after CD3 / CD28 antibody treatment, CD4... + CD25 + T cells, CD4 + CD69 + T cells, CD8 + CD25 + T cells and CD8+ CD69 + The proportion of T cells was increased in all groups, indicating a certain activating effect on T cells. Compared with the untreated group, T cells stimulated by oAd, oAd-FHA-BiTE, and oAd-B7H3-BiTE viral supernatants showed increased CD4 counts. + CD25 + T cells, CD4 + CD69 + T cells, CD8 + CD25 + T cells and CD8 + CD69 + The proportion of T cells was increased in both oAd and oAd-FHA-BiTE, and the supernatant of oAd-B7H3-BiTE stimulated T cells with CD4+. + CD25 + T cells, CD4 + CD69 + T cells, CD8 + CD25 + T cells and CD8 + CD69 + The proportion of T cells was significantly increased, but there was no significant difference in T cell activation between the oAd-FHA-BiTE and oAd-B7H3-BiTE groups, suggesting that BiTE expressed by both oAd-FHA-BiTE and oAd-B7H3-BiTE can stimulate T cell activation. Specific results are as follows: Figure 3 As shown. Among them, Figure 3 To assess the BiTE-mediated T cell activation in different viral supernatants, CD3+ T effector cells (E) and HCT116 target cells (T) were co-cultured at an E:T ratio of 5:1 with BiTE-containing oncolytic virus supernatant for 24 h, 48 h, and 96 h. The expression levels of CD4, CD8, CD25, and CD69 on the surface of T cells were analyzed by multicolor flow cytometry.
[0162] Example 5: Targeted killing effect of B7H3-CD3 BiTE expressed by oAd-B7H3-BiTE on tumor cells
[0163] 2×10 4 One tumor cell was seeded into a 96-well plate, with three replicates per group. The tumor cells served as target cells (T). After culturing for 24 hours, 1×10⁶ tumor cells were added to the plate. 5Individual T lymphocytes were used as effector cells (E), with an effector cell (E) to target cell (T) ratio of 5:1. Each group was treated with 10 μL of oAd-B7H3-BiTE, oAd-FHA-BiTE, or oAd virus supernatant, respectively. The untreated group served as a control. After culturing at 37°C for 24 hours, the cells were centrifuged at 500g for 5 minutes in 96-well plates. The culture supernatant was collected, and the LDH content in the cell culture supernatant was measured using an LDH-cytotoxicity assay kit (Promega) to evaluate the targeted killing effect of oAd-B7H3-BiTE on tumor cells. The results showed that T cell cytotoxicity was most pronounced under stimulation with oAd-B7H3-BiTE virus supernatant. The cytotoxicity mediated by oAd-FHA-BiTE was significantly lower than that mediated by oAd-B7H3-BiTE. The T cell killing induced by oAd virus supernatant was similar to that of T cells alone against tumor cells. Specific results are as follows: Figure 4 As shown, CD3+ T effector cells (E) and tumor target cells (T) were co-cultured at an E:T = 5:1 with BiTE-containing oncolytic virus supernatant for 24 h. The LDH content in the cell culture supernatant was measured using an LDH-cytotoxicity assay kit to evaluate the targeted killing effect of oAd-B7H3-BiTE on tumor cells.
[0164] Example 6: Effect of oAd-B7H3-CD3 BiTE expression on human T lymphocyte proliferation.
[0165] Tumor cells HCT116 were used at a rate of 1×10 5 10 cells / well were seeded into 24-well plates and incubated overnight at 37°C in a 5% CO2 incubator. Healthy T cells were then seeded and incubated with CFSE at a ratio of 1:1000-2000 (V / V) at 37°C in the dark. Labeling was terminated after 30 min of incubation. Tumor cells were then infected with oAd-B7H3-BiTE, oAd-FHA-BiTE, and oAd-ON, followed by the addition of 7.5 × 10⁻⁶ cells / well. 4 5 T cells (E:T = 5:1) were collected, with the CD3 / CD28 antibody treatment group serving as the positive control. Cells were collected on day 4, and the fluorescence intensity of CFSE in CD3+ T cells was detected by flow cytometry. The results showed that compared with the control virus oAd-ON, the fluorescence intensity of CFSE in T cells treated with oAd-B7H3-BiTE and oAd-FHA-BiTE was significantly reduced, and the number of CD3+ T cells was significantly increased. However, there was no significant difference in T cell proliferation stimulated by oAd-B7H3-BiTE and oAd-FHA-BiTE. Specific results are as follows: Figure 5As shown, CD3+ T effector cells (E) and tumor target cells (T) were co-cultured with BiTE-containing oncolytic virus supernatant for 96 h at an E:T = 5:1 ratio. The fluorescence intensity of CFSE was then detected by flow cytometry to evaluate the effect of oAd-B7H3-BiTE on the proliferation of human T lymphocytes.
[0166] Example 7: Effect of oAd-B7H3-CD3 BiTE expression on the ability of T cells to secrete cytokines
[0167] Tumor cells HCT116 were used at a rate of 1×10 5 100 cells / well were seeded into 24-well plates and incubated overnight at 37°C with 5% CO2; 100 μL of viral supernatant was added to infect tumor cells, and 5 × 10⁻⁶ cells / well were added to the plate. 5 T cells (E:T = 5:1) were used, with the CD3 / CD28 antibody treatment group serving as the positive control and T cells added alone as the negative control. Each group had three replicates. Supernatants were collected after 3 days, and IFNγ and IL2 production were detected according to the ELISA instructions. Results showed that compared to the control viruses oAd-ON and oAd-FHA-BiTE, oAd-B7H3-BiTE significantly increased IFN-γ secretion from T cells. However, there was no statistically significant difference in IL-2 secretion among the three viral stimuli, although there was a significant difference compared to the untreated group. Specific results are as follows: Figure 6 As shown, CD3+ T effector cells (E) and tumor target cells (T) were co-cultured at an E:T ratio of 5:1 and in a supernatant containing BiTE oncolytic virus for 72 h. The ability of human T lymphocytes to produce IFNγ and IL2 was then assessed by ELISA.
[0168] Example 8: Therapeutic effect of oAd-B7H3-BiTE-expressed B7H3-BiTE on HCT116 subcutaneous transplantation mouse model
[0169] A subcutaneous HCT116 tumor model was established using NSG mice. HCT116 tumor cells were subcutaneously inoculated into the right back of each mouse, with 3 × 10⁶ cells per mouse. 6 One tumor cell; after 14 days, the tumor volume was approximately 120 mm. 3 Treatment begins immediately. Intratumoral injection of virus or PBS, with a viral load of 3.5 × 10⁻⁶. 8 PFU / animal, injection volume 100 μl / animal, administered once every 3 days for a total of 3 doses. Activated T cells (1 × 10⁶ cells / animal) were injected via tail vein 48 hours after each viral or PBS injection. 7Each mouse received 200 μl of T cells. Five days after the third T cell injection, mice were sacrificed. Fresh tumor tissue was harvested, reconstituted, and weighed. Results showed that compared to the PBS group, oAd-B7H3-BiTE and oAd-FHA-BiTE single-virus administration had a certain inhibitory effect on tumors, and the tumor-suppressive effect of tail vein injection of T cells was stronger than that of the single-virus group. Specific results are as follows: Figure 7 As shown, single-virus administration of oAd-B7H3-BiTE and oAd-FHA-BiTE significantly reduced tumor volume compared to the PBS group. When oncolytic adenoviruses oAd-B7H3-BiTE and oAd-FHA-BiTE were administered followed by tail vein injection of T cells, tumor growth was inhibited more effectively than with single-virus administration, and the tumor-suppressing effect of oAd-B7H3-BiTE+T cells was stronger than that of the oAd-FHA-BiTE+T cells. After mouse sacrifice, the tumor weight in the oAd-B7H3-BiTE+T group was significantly different from that in the T cell group. The therapeutic effect of B7H3-BiTE expressed by oAd-B7H3-BiTE on tumor-bearing mice was evaluated by constructing an HCT116 subcutaneous tumor model.
[0170] Example 9: Effect of oAd-B7H3-BiTE expression on T lymphocyte infiltration.
[0171] Mice were euthanized after intratumoral administration of oAd-B7H3-BiTE and tail vein injection of T cells. Approximately 0.2g of fresh tumor tissue was harvested, minced, and transferred to 15ml centrifuge tubes. 5ml of digestion solution was added to each tube, and the tubes were shaken at 37°C until no visible tissue fragments remained. The digestion solution was filtered through a 70μM filter, centrifuged at 1500rpm for 3min, and the supernatant was discarded. The cell pellet was washed with PBS, centrifuged, and the supernatant was discarded. The cells were resuspended in 1ml of PBS containing live and dead cell dyes and incubated at room temperature in the dark for 15min. After washing with PBS, the cells were centrifuged, the supernatant was discarded, and the cells were resuspended in PBS and aliquoted into flow cytometry tubes. 1μl of Fcblock was added to each tube, and the tubes were incubated at room temperature in the dark for 10min. Flow cytometry antibodies CD3, CD4, and CD8 were added, and the tubes were incubated at 4°C in the dark for 30min. Each tube was resuspended in PBS, centrifuged, the supernatant was discarded, and the cells were washed again. After resuspending in PBS, the cells were analyzed. The results showed that oAd-B7H3-BiTE+T and oAd-FHA-BiTE+T significantly increased CD4+ T cell infiltration at the tumor site, but did not increase CD8+ T cell infiltration. There was a significant difference between the oAd-B7H3-BiTE+T group and the oAd-ON+T group. The proportion of CD8+ T cells was lower, and there was no significant difference in CD8+ T cell infiltration among the groups. Specific results are as follows... Figure 8As shown, the proportion of CD4+ T cells in the oAd-B7H3-BiTE+T group was 58.81±12.15%, in the oAd-FHA-BiTE+T group it was 45.99±7.89%, in the oAd-ON+T group it was 25.11±11.72%, and in the T group it was 24.11±11.71%. This indicates that oAd-B7H3-BiTE+T and oAd-FHA-BiTE+T can significantly increase the infiltration of CD4+ T cells at the tumor site. Furthermore, there was a significant difference between the oAd-B7H3-BiTE+T group and the oAd-ON+T group. Compared to CD4+ T cell infiltration, the proportion of CD8+ T cells was lower, with the oAd-B7H3-BiTE+T group having a CD8+ T cell proportion of 2.24±0.89%, but there was no significant difference in CD8+ T cell infiltration among the groups. The presence of tumor-infiltrating T lymphocytes was detected by flow cytometry.
[0172] Example 10: Effect of oAd-B7H3-BiTE expression of B7H3-BiTE on Tregs infiltration in tumor tissue
[0173] Mice were euthanized after intratumoral administration of oAd-B7H3-BiTE and tail vein injection of T cells. Tumor tissue was excised, minced, and transferred to centrifuge tubes. 5 ml of digestion solution was added to each tube, and the tubes were shaken at 37°C. The digestion solution was filtered through a 70 μM filter, centrifuged at 1500 rpm for 3 min, and the supernatant was discarded. The cell pellet was washed with PBS, centrifuged again, and the supernatant was discarded. 1 ml of PBS containing live and dead cell dyes was added to resuspend the cells, and the cells were incubated at room temperature in the dark for 15 min. After washing with PBS, the cells were centrifuged again, the supernatant was discarded, and the cells were resuspended in PBS and aliquoted into flow cytometry tubes. 1 μl of Fc block was added to each tube, and the tubes were incubated at room temperature in the dark for 10 min. One hour after cell permeabilization, flow cytometry antibodies CD4, CD25, and FOXP3 were added, and the tubes were incubated at 4°C in the dark for 30 min. Each tube was resuspended in PBS, centrifuged, the supernatant was discarded, and the cells were washed again. After resuspending in PBS, the cells were analyzed. The results showed that oAd-B7H3-BiTE+T and oAd-FHA-BiTE+T significantly reduced the infiltration of Treg cells at the tumor site. Specific results are as follows: Figure 9 As shown, the proportion of Treg cells in the oAd-B7H3-BiTE+T group was 9.51%, in the oAd-FHA-BiTE+T group it was 22.22%, and in the oAd-ON+T group it was 32.15%. This indicates that oAd-B7H3-BiTE+T and oAd-FHA-BiTE+T can significantly reduce the proportion of Treg cells in the tumor site, while there is no significant difference in the proportion of Treg cells between the oAd-B7H3-BiTE+T and oAd-FHA-BiTE+T groups.
Claims
1. An oncolytic adenovirus expressing a bispecific T-cell connective, characterized in that: Including oncolytic adenovirus E1A and E1B gene expression cassettes, and B7H3×CD3 BiTE exogenous gene expression cassette; The oncolytic adenovirus E1A and E1B gene expression cassette includes the following operatively linked elements: human telomerase promoter hTERTp, E1A gene, IRES sequence, E1B gene, and SV40 PolyA terminator. The nucleotide sequence of the human telomerase promoter hTERTp is shown in SEQ ID NO:1; The nucleotide sequence of the E1A gene is shown in SEQ ID NO:2; The IRES nucleotide sequence is shown in SEQ ID NO:4; The nucleotide sequence of the E1B gene is shown in SEQ ID NO:5; The nucleotide sequence of the SV40 PolyA is shown in SEQ ID NO:8; The B7H3×CD3 BiTE exogenous gene expression cassette includes the following operatively linked elements: promoter, signal peptide coding sequence, B7H3 scFv light chain variable region coding sequence, linker sequence 1, B7H3 scFv heavy chain variable region coding sequence, linker sequence 2, CD3 scFv, and terminator. The signal peptide is an Igκ signal peptide, and its nucleotide sequence is shown in SEQ ID NO:9; The nucleotide sequence of the variable region of the light chain of B7H3 scFv is shown in SEQ ID NO:12; The linker peptide of linker sequence 1 is (G4S)3, and its nucleotide sequence is shown in SEQ ID NO:19; The nucleotide sequence of the variable region of the B7H3 scFv heavy chain is shown in SEQ ID NO:16; The nucleotide sequence of linker sequence 2 is shown in SEQ ID NO:23; The nucleotide sequence of CD3 scFv is shown in SEQ ID NO:
21.
2. The oncolytic adenovirus expressing a bispecific T-cell connective according to claim 1, characterized in that: Oncolytic adenovirus E1A is controlled by the human telomerase promoter hTERTp.
3. The oncolytic adenovirus expressing a bispecific T-cell connector according to claim 2, characterized in that: E1A connects to the internal ribosome entry site IRES and initiates E1B expression, forming an oncolytic adenovirus with the structure hTERTp-E1A-IRES-E1B.
4. The oncolytic adenovirus expressing a bispecific T-cell connective according to claim 3, characterized in that: The amino acid sequence of the E1A gene is shown in SEQ ID NO:3; The amino acid sequences of E1B19K and E1B55K encoded by the E1B gene are shown in SEQ ID NO:6 and SEQ ID NO:7, respectively.
5. The oncolytic adenovirus expressing a bispecific T-cell connective according to claim 1, characterized in that: The B7H3×CD3 BiTE exogenous gene expression cassette also includes a Kozak sequence preceding it, and the promoter includes a eukaryotic promoter; the eukaryotic promoter is CMV, mCMV or CAG.
6. The oncolytic adenovirus expressing a bispecific T-cell connective according to claim 1, characterized in that: The amino acid sequence of the Igκ signal peptide is shown in SEQ ID NO:10; The amino acid sequence of the variable region of the light chain of B7H3 scFv is shown in SEQ ID NO:14; The amino acid sequence of the variable region of the B7H3 scFv heavy chain is shown in SEQ ID NO:18; The amino acid sequence of linker peptide (G4S)3 is shown in SEQ ID NO:20; The amino acid sequence of CD3 scFv is shown in SEQ ID NO:22; The amino acid sequence of the linker peptide between B7H3 scFv and CD3 scFv is shown in SEQ ID NO:
24.
7. A recombinant oncolytic adenovirus vector, characterized in that: It can be operatively inserted into or contain the B7H3×CD3 BiTE exogenous gene expression cassette as described in claim 1.
8. The method for constructing an oncolytic adenovirus expressing a bispecific T-cell connective according to any one of claims 1-6, characterized in that: Includes the following steps: The synthesized E1A-E1B gene expression cassette was cloned into a shuttle vector to construct a plasmid containing E1A-E1B gene expression. The synthesized B7H3×CD3 BiTE gene was then cloned into the plasmid containing E1A-E1B gene expression. Finally, the recombinant adenovirus was packaged to obtain a recombinant oncolytic adenovirus expressing B7H3×CD3 BiTE.
9. The method for constructing an oncolytic adenovirus expressing a bispecific T-cell connective according to claim 8, characterized in that: Includes the following steps: The E1A-E1B gene expression cassette was synthesized and cloned into a shuttle vector using the Gibson cloning method to construct a plasmid containing E1A-E1B gene expression. The B7H3×CD3 BiTE gene was then cloned into the pDC316 or pDC516 shuttle plasmid. The pDC316 or pDC516 shuttle plasmid carrying the B7H3×CD3 BiTE gene was co-transfected into HEK293 cells with the backbone plasmid of the AdMax adenovirus packaging system to package recombinant adenovirus, thus obtaining a recombinant oncolytic adenovirus expressing B7H3×CD3 BiTE.
10. The method for constructing an oncolytic adenovirus expressing a bispecific T-cell connective according to claim 9, characterized in that: The backbone plasmid includes pBHGlox_E1,3Cre or pBHGfrt_E1,3Flp.
11. Use of the oncolytic adenovirus expressing a bispecific T-cell connective according to any one of claims 1-6 or the recombinant oncolytic adenovirus vector according to claim 7 in the preparation of a medicament for the treatment and / or prevention and / or adjuvant treatment of tumors.
Citation Information
Patent Citations
Multi-gene fusion oncolytic adenovirus and construction method and application thereof
CN113699122A
RECOMBINANT SEROTYPE 5 (Ad5) ADENOVIRAL VECTORS
US20150232811A1
